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doi:10.1016/j.jtcvs.2003.11.0321262 The Journal of Thoracic and CardObjective: Myocardial injury and dysfunction following ischemia are mediated
in part by reactive oxygen species. Pyruvate, a key glycolytic intermediary, is an
effective free radical scavenger but unfortunately is limited by aqueous insta-
bility. The ester derivative, ethyl pyruvate, is stable in solution and should
function as an antioxidant and energy precursor. This study sought to evaluate
ethyl pyruvate as a myocardial protective agent in a rat model of ischemia-
reperfusion injury.
Methods: Rats underwent 30-minute ischemia and 30-minute reperfusion of the left
anterior descending coronary artery territory. Immediately prior to both ischemia
and reperfusion, animals received an intravenous bolus of either ethyl pyruvate (n
 26) or vehicle control (n  26). Myocardial high-energy phosphate levels were
determined by adenosine triphosphate assay, oxidative injury was measured by lipid
peroxidation assay, infarct size was quantified by triphenyltetrazolium chloride
staining, and cardiac function was assessed in vivo.
Results: Ethyl pyruvate administration significantly increased myocardial adenosine
triphosphate levels compared with control (87.6  29.2 nmol/g vs 10.0  2.4
nmol/g, P  .03). In ischemic myocardium, ethyl pyruvate reduced oxidative injury
compared with control (63.8  3.3 nmol/g vs 89.5  3.0 nmol/g, P  .001). Ethyl
pyruvate diminished infarct size as a percentage of area at risk (25.3%  1.5% vs
33.6%  2.1%, P  .005). Ethyl pyruvate improved myocardial function compared
with control (maximum pressure: 86.6  2.9 mm Hg vs 73.5  2.5 mm Hg, P 
.001; maximum rate of pressure rise: 3518  243 mm Hg/s vs 2703  175 mm
Hg/s, P  .005; maximal rate of ventricular systolic volume ejection: 3097  479
L/s vs 2120  287 L/s, P  .04; ejection fraction: 41.9%  3.8% vs 31.4% 
4.1%, P  .03; cardiac output: 26.7  0.9 mL/min vs 22.7  1.3 mL/min, P  .01;
and end-systolic pressure-volume relationship slope: 1.09  0.22 vs 0.59  0.2, P
 .02).
Conclusions: In this study of myocardial ischemia-reperfusion injury, ethyl pyruvate
enhanced myocardial adenosine triphosphate levels, attenuated myocardial oxida-
tive injury, decreased infarct size, and preserved cardiac function.
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PMyocardial dysfunction and injury fol-lowing ischemia are attributed tomultiple factors, of which metabolicdepletion of high-energy phosphatesand formation of reactive oxygen spe-cies (ROS) are perhaps most predom-
inant. During ischemia, without citric acid cycle contribu-
tion, energy requirements are poorly met by anaerobic
glycolysis. Finely controlling glycolysis are multiple regu-
lators including substrate limitation, oxidized nicotinamide
adenine dinucleotide (NAD), and allosterically governed
enzymes. Researchers have attempted various approaches
toward glycolytic substrate enhancement to augment aden-
osine triphosphate (ATP) production. Pyruvate, one such
extensively studied efficacious glycolytic intermediate,
yields increased cytosolic NAD, the obligate electron ac-
ceptor for glyceraldehyde-3-phosphate dehydrogenase,
which oxidizes glyceraldehyde-3-phosphate to 1,3 bisphos-
phoglycerate.1-4 In turn, phosphoglycerate kinase can then
catalyze 1,3 bisphosphoglycerate to 3-phosphoglycerate
generating ATP, augmenting cardiomyocyte energetics.1
The second primary mechanism of injury involves the
generation of ROS during reperfusion via multiple reac-
tions, most notably:
xanthine oxidase: 2O2  NADPH 3 2O2  NADP 
H
superoxide dismutase: 2O2  2H 3 H2O2
nitric oxide: O2  NO 3 ONOO
ionized iron: H2O2  Fe2 3 OH  OH  Fe3
Superoxide anion (O2) and hydrogen peroxide (H2O2) are
moderately reactive, whereas peroxynitrite (ONOO) and
hydroxyl radical (OH) are highly toxic and produce a
spectrum of cellular injury via multiple mechanisms includ-
ing membrane destabilization, mitochondrial disruption,
and metabolic derangement. There exists a battery of native
antioxidant enzyme systems that sequentially convert ROS
to water and oxygen:
superoxide dismutase: 2O2  2H 3 H2O2  O2
catalase: 2H2O2 3 2H2O  O2
glutathione peroxidase: H2O2  2GSH 3 2H2O  GSSG
where GSH is reduced glutathione and GSSG is oxidized
glutathione. Multiple strategies for augmenting these native
systems have likewise been investigated.5-8
Interestingly pyruvate, in the presence of hydrogen per-
oxide, will decarboxylate to yield acetate, water, and carbon
dioxide.9 Pyruvate is also capable of scavenging hydroxyl
radical.10 Studies have shown that exogenous pyruvate ad-
ministration diminishes ischemic myocardial oxidative in-
jury,11-14 apparently in a dose-dependent manner.15 Further-
more, independent of its metabolic and antioxidant features,
pyruvate may possess myocardial inotropic properties.
The Journal of ThoracicPyruvate directly increases sarcoplasmic reticular ATPase
activity and hence calcium cycling efficiency.15 In addition,
pyruvate also indirectly augments beta agonist–mediated
inotropy.16 Unfortunately, the therapeutic potential of ex-
ogenously administered pyruvate is significantly limited by
extreme aqueous instability. Pyruvate can undergo sponta-
neous condensation to parapyruvate, which can further un-
dergo cyclization and either dehydration or reduction to
yield a purported mitochondrial inhibitor.17,18
Ethyl pyruvate, a commercial food additive, is a li-
pophilic ester derivative of pyruvate. Although poorly sol-
uble in water or saline, ethyl pyruvate is highly soluble in
calcium solutions, forming a dimolecular complex of the
anionic enolate form stabilized with divalent cationic calci-
um.19 In this form, ethyl pyruvate possesses far greater
stability than pyruvate and hence may serve as a practical
pyruvate precursor.
We therefore hypothesized that in a model of myocardial
ischemia-reperfusion injury, ethyl pyruvate administration
would provide a cardioprotective effect.
Methods
Animal Care and Biosafety
Male Wistar rats weighing 250 to 350 g were obtained from
Charles River (Boston, Mass). Food and water were provided ad
libitum. This study was performed in accordance with the standard
humane care guidelines of the Institutional Animal Care and Use
Committee of the University of Pennsylvania, which conform to
current federal guidelines.
Preparation of Treatment Solutions
Experimental treatment groups were divided into animals receiv-
ing Ringer’s solution as a control or Ringer’s solution containing
28 mmol/L ethyl pyruvate obtained from Sigma Chemicals (St
Louis, Mo). Ringer’s solution contained 130 mmol/L Na, 4.0
mmol/L K, 2.7 mmol/L Ca2, and 109 mmol/L Cl at pH 7.0.
Acute in Vivo Ischemia-Reperfusion Model
Animals (n  52) underwent induction of general anesthesia with
ketamine (75 mg/kg) and xylazine (7.5 mg/kg), endotracheal in-
tubation with a 14-gauge angiocatheter, and mechanical ventilation
with 2% isofluorane maintenance anesthesia with a respirator
(Hallowell EMC, Pittsfield, Mass). Venous access for administra-
tion of treatment solutions was obtained via exposure of the right
femoral vein and insertion of a 24-gauge intravenous catheter. A
left thoracotomy was performed through the fourth intercostal
space and the pericardium was reflected, exposing the heart. A 7-0
polypropylene suture was then placed around the left anterior
descending (LAD) coronary artery and briefly snared to visually
verify the territory of myocardial ischemia. Animals were then
randomized to either the control (n  26) or ethyl pyruvate group
(n  26) and received a 1.5 mL/kg intravenous bolus of either
Ringer’s solution or ethyl pyruvate. Two minutes later, ischemia
was initiated. The LAD was then occluded for 30 minutes. In a
small subset of animals (control n  5, ethyl pyruvate n  5),
hearts were harvested 10 minutes into the ischemia period for
and Cardiovascular Surgery ● Volume 127, Number 5 1263
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CSPanalysis of myocardial energetic state via ATP assay. In the other
42 animals, after the 30-minute ischemic period, just prior to
reperfusion, the treatment solution was again intravenously bo-
lused (3.0 mL/kg). Hearts were then reperfused for 30 minutes. At
the end of this period, the animals were either put to death and
hearts were harvested for lipid peroxidation analysis (control n 
6, ethyl pyruvate n  6) or animals were prepared for cardiac
functional assessment and subsequent heart explantation for infarct
size determination (control n  15, ethyl pyruvate n  15).
Myocardial ATP Levels
ATP levels were quantified using the commercially available EN-
LITEN ATP luciferin/luciferase bioluminescence assay system
(Promega, Madison, Wis). Myocardial tissue specimens from the
ischemic region were excised, immediately frozen in liquid nitro-
gen, and individually pulverized into a fine powder by hand
grinding with a dry ice–chilled steel mortar and pestle.20 Ten
milligrams of myocardium were homogenized with 1 mL of pre-
cooled extractant (0.1% trichloroacetic acid) and centrifuged at
4500 revolutions per minute (rpm) for 10 minutes.21 Supernatant
(100 L) was diluted 10-fold with 50 mmol/L Tris-acetate buffer
containing 2 mmol/L ethylenediaminetetraacetic acid (pH 7.75).
Then 100 L of sample extract or reference standard solution was
placed in a tube luminometer (Turner Designs Luminometer TD-
20/20, Promega), followed by the auto-injection of 100 L of ATP
luciferin/luciferase assay mix for ATP quantification. Lumines-
cence was measured at a set lag time of 1 second and integration
time of 10 seconds.
Myocardial Lipid Peroxidation Measurements
Myocardial lipid peroxidation was quantified using the commer-
cially available PeroxiDetect KIT (Sigma Chemicals). Myocardial
tissue specimens were obtained from the ischemic anterolateral left
ventricular wall and from the nonischemic remote basal postero-
septal left ventricle and immediately frozen in liquid nitrogen.
Lipid soluble components were extracted from the myocardial
22
Figure 1. ATP levels measured bioluminescently in ischemic
myocardium 10 minutes after the initiation of ischemia. Signifi-
cantly higher levels of ATP were observed in ethyl pyruvate–
treated hearts (n  5) compared with controls (n  5).tissue specimens using a CHCl3/methanol extraction protocol.
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volume mixture of CHCl3 and 100% methanol at a ratio of 1 g
tissue to 15 mL of the CHCl3/methanol mixture. The homogenized
material was centrifuged at 10,000 rpm for 10 minutes, after which
the supernatant was clarified with 0.3 mL of 0.9% NaCl per 1 g of
tissue and then removed. The CHCl3 layer was then evaporated
with nitrogen gas to leave the lipid peroxides from the specimens
contained in the methanol solvent. Specimen samples (100 L)
were added to a 1-mL mixture of Fe2 ion and xylenol orange.
Peroxides convert Fe2 to Fe3, which forms a color adduct with
xylenol orange spectrophotometrically detectable at 560 nm. Lipid
peroxide levels were then calculated using a reference standard
curve generated with defined quantities of tert-butyl hydroperox-
ide.
Cardiac Functional Assessment Following Ischemia
and Reperfusion
Following the 30-minute reperfusion period, a median sternotomy
was performed and myocardial performance was assessed in vivo
(control n  15, ethyl pyruvate n  15). A fully calibrated
miniature pressure/volume conductance catheter (MIKRO-TIP
catheter and ARIA Pressure Volume Conductance System, Millar
Instruments, Houston, Tex) was inserted into the left ventricular
cavity through the apex. Calibration consisted of the cuvette
2-point linear interpolation process and parallel conductance sub-
traction via the hypertonic saline method. The digitized pressure
and volume signals were displayed and recorded using Chart
v4.1.2 software (AD Instruments, Colorado Springs, Colo). Mul-
tiple cardiac functional parameters were measured in the 2 groups
using Cardiac Pressure Volume Analysis Software-PVAN 2.9
(Millar Instruments). Additionally, a flow probe monitor (Tran-
sonic Systems, Ithaca, NY) was placed around the ascending aorta
to measure cardiac output. To provide a reference of baseline rat
myocardial function, a separate group of 15 noninfarcted native
animals underwent pressure-volume and cardiac output analysis.
Planimetric Determination of Left Ventricular
Infarction Size
Following the cardiac functional analysis, control and ethyl pyru-
vate hearts were excised and rinsed in normal saline solution (pH
7.4). The LAD was again snared and Evans blue dye was infused
into the aortic root to facilitate determination of area at risk. The
specimens were cut perpendicular to the long axis into 5 sections
and incubated in 1% triphenyltetrazolium chloride (TTC) (Sigma
Chemicals) in phosphate-buffered saline solution (pH 7.4) at 37°C
for 20 minutes. Following the incubation period, the TTC was
rinsed from the sections and a 10% formalin solution was added
for tissue fixation. Sections were photographed using a digital
camera and were downloaded onto a desktop computer containing
digital planimetry software (OpenLab, Lexington, Mass). Infarct
size as a percentage of area at risk was then measured.
Statistical Methods
Statistical analyses were performed using unpaired, 1-tailed Stu-
dent t tests. All results were expressed as mean standard error of
the mean (SEM).
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Analysis of ATP levels in ischemic hearts revealed a
marked increase in animals receiving ethyl pyruvate com-
pared with control animals (Figure 1). The ischemic region
of control hearts contained 10.0  2.4 nmol/g, whereas the
ischemic region of ethyl pyruvate hearts contained 87.6 
29.2 nmol/g (P  .03).
Lipid Peroxidation Analysis
Spectrophotometric quantification of lipid peroxides in
myocardium exposed to ischemia and reperfusion and in
nonischemic myocardium, which served as an internal con-
trol, is represented in Figure 2. Lipid peroxide levels in the
nonischemic myocardium did not differ significantly be-
tween animals treated with ethyl pyruvate (42.3  4.8
nmol/g; n  6) and the control, Ringer’s solution (37.5 
5.1 nmol/g; n  6), implying equivalent assay conditions
between control and ethyl pyruvate hearts. Ischemia signif-
icantly increased the level of lipid peroxidation from 37.5
5.1 nmol/g to 89.5  3.0 nmol/g in control hearts (P 
.001). When comparing ischemic myocardium in ethyl
pyruvate hearts with control hearts, there was a statistically
significant decrement in lipid peroxidation with ethyl pyru-
vate administration (63.8  3.3 vs 89.5  3.0 nmol/g, P 
Figure 2. Lipid peroxidation in myocardium following ischemia
and reperfusion. Lipid peroxidation in remote nonischemic myo-
cardium was equivalent between control (n  6) and ethyl
pyruvate (n  6) hearts. Ischemia increased the level of lipid
peroxidation in the control hearts. The administration of ethyl
pyruvate decreased the level of lipid peroxidation in the ischemic
myocardium when compared with control hearts..001).
The Journal of ThoracicInfarction Analysis
Macroscopic analysis of TTC-stained cross sections follow-
ing 30 minutes of ischemia and 30 minutes of reperfusion
demonstrated attenuated left ventricular infarction sizes in
animals treated with ethyl pyruvate (n  15) as compared
with the control group (n  15; Figure 3). Ethyl pyruvate
animals had 25.3%  1.5% of the left ventricular area at
risk infarcted as compared with 33.6%  2.1% in control
animals (P  .005).
Cardiac Function
Table 1 displays heart rate and multiple pressure and vol-

















98.7 2.9 73.5 2.5 86.6 2.9 .001
Maximum dP/dt
(mm Hg/s)
4974 199 2703 175 3518 243 .005
Minimum dP/dt
(mm Hg/s)
3940 2581745 170 2841 329 .003
Maximum dV/dt
(L/s)
3919 321 2120 287 3097 479 .04
Ejection fraction
(%)
47.1 3.3 31.4 4.1 41.9 3.8 .03
Cardiac output
(mL/min)
33.0 1.8 22.7 1.3 26.7 0.9 .01
bpm, Beats per minute; dP/dt, rate of pressure rise; dV/dt, rate of ventric-
ular systolic volume ejection.
Figure 3. Myocardial infarction percentage measured by infarc-
tion area (IA)/area at risk (AAR) following ischemia and reperfu-
sion. Significant differences in left ventricular infarction were
observed between animals receiving ethyl pyruvate (n  15) and
the control group (n  15).ume parameters for native animals (n  15) as a reference,
and Cardiovascular Surgery ● Volume 127, Number 5 1265
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animals (n  15). Statistical comparisons between control
and ethyl pyruvate animals are displayed. Heart rates were
equivalent. In all pressure and volume parameters mea-
sured, there was a statistically significant increase in cardiac
function among ethyl pyruvate animals compared with con-
trols. The administration of ethyl pyruvate to infarcted an-
imals brought hemodynamic parameters partially back to
those levels observed among noninfarcted native animals.
End-systolic pressure-volume relationships were assessed
and represented as a regression composite for each of the 3
groups (Figure 4). Ethyl pyruvate animals exhibited signif-
icantly improved myocardial function compared with con-
trol animals, approaching native baseline values.
Discussion
Ischemia-reperfusion injury of myocardium is a significant
entity in many clinical situations, including coronary throm-
bolysis, percutaneous coronary interventions, cardiac sur-
Figure 4. Composite representation of end-systolic pressure-vol-
ume relationships (ESPVR) in native animals (n  15) and in
control (n  15) and ethyl pyruvate–treated (n  15) animals
following ischemia and reperfusion. For native animals, mean 
SEM slope, x-axis intercept (x-int), and correlation coefficient (r)
were: 1.27  0.12, 10.4  2.0, and 0.97  0.07, respectively. For
control animals, the values were: slope  0.59  0.2, x-int  9.9
 24.0, r  0.68  0.13; for ethyl pyruvate–treated animals, these
values were: slope  1.09  0.22, x-int  4.1  19.9, r  0.89
 0.03. Comparing the slopes of the control and ethyl pyruvate
hearts demonstrates a statistically significant improvement in
contractility with the administration of ethyl pyruvate (P  .02).
Composite ESPVR for the native animals (n  15) was 1.27
(end-systolic volume [ESV]-10.39), control (n  15) was 0.59
(ESV-9.88), and ethyl pyruvate (n  15) was 1.09 (ESV-4.06).
Significant differences in the slope of the ESPVR were found
between ethyl pyruvate and control animals.gery, and heart transplantation. Myocardial dysfunction and
1266 The Journal of Thoracic and Cardiovascular Surgery ● Macellular injury occurs in part due to metabolic depletion
during ischemia followed by ROS formation during reper-
fusion. Significant research efforts have investigated means
of protecting myocardium against ischemia-reperfusion in-
jury. This article describes our utilization of ethyl pyruvate
as an intravenous myocardial protection agent. Rats re-
ceived bolus ethyl pyruvate before temporary coronary li-
gation and just before reperfusion and demonstrated statis-
tically significantly increased myocardial ATP levels,
decreased tissue oxidative injury, decreased infarct sizes,
and preserved myocardial function. To our knowledge, this
is the first report of a cardiovascular application of this
agent.
Ethyl pyruvate’s parent compound, the glycolytic prod-
uct pyruvate, has been shown to attenuate myocardial isch-
emic injury through both metabolic augmentation and anti-
oxidant mechanisms but is limited in potential therapeutic
efficacy by extreme aqueous instability.1,12,17 Specific stud-
ies into the metabolic activity of the related pyruvate ester,
methyl pyruvate, in pancreatic islet cells have demonstrated
cellular and mitochondrial membrane permeation, deesteri-
fication liberating free pyruvate for glycolytic substrate uti-
lization, and subsequent augmentation of ATP generation.23
These studies, which were performed on nonischemic cells,
also found a disproportionate increase in ATP generation
compared with glucose utilization. This enhanced produc-
tion of ATP is felt to result from rapid intracellular dees-
terification of methyl pyruvate to pyruvate and thus the
generation of a significant transcellular gradient favoring
further intracellular influx of methyl pyruvate. This results
in the rapid accumulation of an intracellular excess pool of
pyruvate generated free of glycolytic regulators and without
the obligate initial ATP investment at the glucokinase and
phosphofructokinase reactions. Pyruvate is then available
for pyruvate dehydrogenase conversion to acetyl CoA and
citric acid cycle substrate provision.2 Such pyruvate stores
may be particularly useful in the myocardial reperfusion
phase when the citric acid cycle becomes available again,
yet ATP levels are very low and require rapid repletion.
Biologic investigation of ethyl pyruvate was first de-
scribed in ophthalmologic research aimed at the prevention
of free radical–induced lens injury, which normally leads to
cataract formation.24,25 Ethyl pyruvate has subsequently
been studied in the trauma/critical care literature with mod-
els of mesenteric ischemia, hemorrhagic shock, and endo-
toxemic sepsis, all demonstrating a cytoprotective ef-
fect.19,26-29 Another postulated role of ethyl pyruvate is
related to its anti-inflammatory properties. In a murine hem-
orrhagic shock model, ethyl pyruvate decreased expression
of tumor necrosis factor and interleukin-6.26 This could be
explained as an indirect finding related to ethyl pyruvate–
mediated attenuation of multiorgan ischemic injury from the
induced state of hemorrhagic shock. In vitro, ethyl pyruvate
y 2004
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Pdoes appear to directly inhibit the nuclear factor B– and
p38 mitogen–activated protein kinase pathways of inflam-
matory cytokine activation. To date, there has not been a
report of the application of ethyl pyruvate to the cardiovas-
cular system.
This study sought to investigate the potential effect of
exogenous ethyl pyruvate administration on reducing myo-
cardial injury and contractile dysfunction after ischemia.
The overall design of this study evaluated the effects of
ethyl pyruvate at biochemical, cellular, and physiologic
levels. Myocardial high-energy phosphate levels, free radi-
cal injury, myocardial infarction, and cardiac mechanics
were examined in a model of myocardial ischemia-reperfu-
sion injury. The proportionate degree of myocardial injury
induced is more pronounced than what occurs in a typical
cardiac surgical procedure. Nevertheless, the model was
selected for its predictability and functionality.
In the control group, Ringer’s solution was utilized to
preclude any attribution of observed differences to electro-
lyte composition of solutions. Also, in the unlikely event
that some acid-base buffering capacity of ethyl pyruvate
was the only cause of observed differences, we also per-
formed a small pilot series of control animals with lactated
Ringer’s solution. These animals would have obtained any
buffering benefit, yet myocardial function and infarct size
were equivalent to Ringer’s solution controls. The dose of
ethyl pyruvate selected for this study was based upon a
concentration of ethyl pyruvate previously optimized in an
intestinal ischemia model.19 The timing of administration of
the ethyl pyruvate was designed to enhance the two pur-
ported mechanisms of action, glycolytic substrate augmen-
tation and antioxidation.
An initial left thoracotomy was employed during the
ischemic period for several reasons. This permitted ease of
access to the LAD, ease of confirmation of a large antero-
lateral region of ischemic discoloration, and absence of
sternal bleeding during this period. A sternotomy was then
utilized for hemodynamic assessment because this allowed
a more favorable angle of entry of the pressure-volume
conductance microcatheter into the left ventricle. In the rat,
catheter insertion from a thoracotomy approach causes left-
ward displacement of the cardiac apex with resultant torsion
on the heart and hemodynamic compromise similar to that
seen clinically when displacing the heart during off-pump
grafting of lateral coronary arteries. Furthermore, a sternot-
omy facilitated easier access to the inferior vena cava for
load variation to assess pressure-volume relationships.
To confirm the proposed mechanism of action of ethyl
pyruvate attributed to glycolytic substrate augmentation,
tissue ATP levels were assayed in the ischemic myocardial
territory 10 minutes after LAD snaring. This period of time
was chosen to permit depletion of potentially confounding
myocardial high-energy phosphate reserves as well as to
The Journal of Thoracicensure dependence upon anaerobic glycolysis. As described
above, excess exogenous pyruvate could liberate NAD for
more proximal glycolytic pathway generation of ATP.
Myocardial oxidative injury was diminished with ethyl
pyruvate. Compared with other inferential assays of free
radical injury, such as measuring GSH/GSSG levels, the
lipid peroxidation assay is a direct measure of free radical
tissue injury. In this study, both an internal control within
each heart of ischemic versus nonischemic tissue and an
external control of ethyl pyruvate–treated hearts versus
Ringer’s control hearts were employed. The equivalent re-
sults in nonischemic tissue between ethyl pyruvate and
control groups further validated both the model and the
assay. The reduction in lipid peroxidation of the ethyl pyru-
vate group as compared with the control group is an indi-
cation of reduced free radical injury in the animals treated
with ethyl pyruvate.
Clearly, further studies are warranted. Future investiga-
tions should evaluate ethyl pyruvate’s myocardial protective
capacity in other models of myocardial ischemia as a means
of broadening the spectrum of clinical utility. To more
closely mimic the typical ischemia occurring during on-
pump cardiac surgery, the duration or proximity of ligation
could be altered to decrease the extent of myocardial injury.
Shorter, transient periods of localized ischemia could be
produced to better model off-pump coronary surgery or
percutaneous coronary interventions.
Future directions should determine whether using higher
doses of ethyl pyruvate yields even greater myocardial
protective effects. Presently, only a limited dose-response
curve of 3 concentrations of ethyl pyruvate spanning 3 logs
has been studied.15 Alternate routes of administration, par-
ticularly intracoronary, should also be evaluated to search
for increased efficacy. A dual intravenous bolus technique
was utilized with the assumption that a continuous infusion
during the period of coronary occlusion may not be useful.
Alternate timing strategies should also be evaluated, such as
prolonged pretreatment, continuous treatment, and postre-
perfusion continuous infusion. Finally, ethyl pyruvate
should also be evaluated as an additive to transplant organ
preservation solutions.
In this study, ethyl pyruvate—a nontoxic, inexpensive,
intravenously administered antioxidant and potential glyco-
lytic substrate—significantly preserved cardiac function,
enhanced tissue ATP levels, attenuated myocardial oxida-
tive injury, and markedly reduced infarct size after pro-
longed myocardial ischemia.
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Discussion
Dr W. Randolph Chitwood, Jr (Greenville, NC). What other
mechanisms might be being involved here besides peroxidation?
Dr Woo. The data that we show relates primarily to the
antioxidant aspects and that’s been well shown with pyruvate. We
are very interested in evaluating the potential ability to augment
glycolysis. I just bought a luminometer, and we’re going to look at
ATP levels through a luciferin-luciferase assay to see if there is
any augmentation of the total cellular bioenergetic state.
Dr Jakob Vinten-Johansen (Atlanta, Ga). Can you tease out
the functional recovery aspects that you demonstrated? Because
you have an agent that exhibits positive inotropic effects, antiox-
idant effects, and also metabolic support effects; any 1 of those 3
could be responsible for the functional recovery you observed. The
reduction in the infarct size by itself perhaps could be responsible
for that improvement in function.
In addition, when you looked at the ejection fraction, did you
have a control group to which you could compare that ejection
fraction? In other words, was it actually an increase in the treated
group relative to baseline, or does ejection fraction return to a
baseline level?
Dr Woo. In terms of your first question, that’s sort of what I
think Dr Chitwood was alluding to, whether or not there was
something else going on. You, of course, have accurately defined
what we have proposed in our background as the 3 primary
mechanisms. And again, we have the data for the antioxidant effect
and we’re starting the bioenergetics aspect.
I haven’t really thought about how to get at the direct inotropy
aspect. There is, I think, a lot more support for pyruvate’s antiox-
idant and metabolic aspects and less so for its direct inotropy, so
I think that that is perhaps a little less likely to yield something.
In terms of how to distinguish all 3, that’s obviously going to
be of interest. We could, of course, try to block out 1 of those
pathways, perhaps by augmenting free radical production to try to
overwhelm the antioxidant effects and then see, so on and so forth.
In terms of your second question, we did not measure baseline
levels of ejection fraction in these animals. But in our separate
pilot studies where we were basically working out the details of the
Millar catheter, also as part of also our heart failure studies, we do
have a sense of where ejection fraction lies and it’s generally in the
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P40% to 50% range, so there is a decrement even in the treated
animals. They do have an 8% infarct and they are just status
post–significant ischemic injury. So we don’t necessarily expect
them to get back to a baseline level, but it’s mostly the difference
between the 2 groups that we’re looking at.
Dr Vinten-Johansen. You gave the injections or the adminis-
trations at ischemia and reperfusion to take advantage of both the
metabolic effects as well as the antioxidant effects, is that the
rationale?The Journal of ThoracicDr Vinten-Johansen. How did you decide on the dosage, the
concentration that you gave?
Dr Woo. We were guided somewhat by the intestinal ischemic-
reperfusion work, although that’s just a starting point. There is no
dose-dependent evaluation of ethyl pyruvate in the literature for
any of the other trauma critical care work. There are only maybe
5 published studies, period, looking at anything physiologic.
In terms of pyruvate, there is a dose-dependent benefit. So we
could potentially shoot for an equimolar concentration of pre-Dr Woo. That’s right. sumed pyruvate release as another target point.and Cardiovascular Surgery ● Volume 127, Number 5 1269
